000			03581nam a2200325 i 4500
999			_c402314 _d402314
001			402314
003			ES-MaUEC
005			20240617174835.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			230301s2023 si | fo |||| 0|eng d
020			_a9789811976308
024	7		_a10.1007/978-981-19-7630-8 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280 .B8 _b2023 EB
245	0	0	_aScreening and Risk Reduction Strategies for Breast Cancer : _bImaging Modality and Risk-Reduction Approaches _cedited by Masakazu Toi
250			_a1st ed. 2023
264		1	_aSingapore _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1. Introduction of the whole issue -- 2. Breast cancer epidemiology: incidence, risks and subtype -- 3. Personalized genetic breast cancer risk estimation with polygenic risk scores -- 4. Mathematical model forassessing breast cancer risk -- 5. Cost-effectiveness Analysis of multigene testing -- 6. Hereditary breast cancer: Its biology, subtype and clinical phenotype -- 7. Surgical risk reduction of breast cancer -- 8. Medical risk reduction of breast cancer -- 9. Screening for breast cancer with mammography -- 10. Breast cancer screening: Weighing the benefits and harms -- 11. Breast cancer screening according to individual risk -- 12. MRI: Detection of noninvasive diseases -- 13. Significance of MRI for women having dense breasts -- 14. Ultrasound: screening of breast cancer -- 15. Detection of breast cancer by PET -- 16. Radiowave mammography -- 17. Photoacoustic imaging of breast cancer.
520			_aThis book provides readers with the most up-to-date practical information on breast cancer screening. Since breast cancers are highly heterogeneous, time to clinical onset from the initial carcinogenesis differs diversely between cancers. Pathological germline variants and driver mutations cause a high lifetime risk of breast cancer. The lifetime risks are various according to what genes are pathologically dysfunctional. Integrated omics and imaging technologies have established varying tumour characteristics. Thus, this book suggests that a more individualised scheme is required to improve breast cancer screening. A key aim is to demonstrate how multiple diagnostic imaging modalities such as mammography, ultrasonography, MRI, PET and dbPET improve breast cancer screening accuracy. Mammography screening alone may have a limited impact on breast cancer risk prediction. These issues are crucial to discuss. Clinical experts recommend that new modalities be incorporated for women with dense breasts, like ultrasonography, dynamic mammography, MRI and maybe breast-dedicated PET. Topics on these modalities are going to be summarized in this book. An in-depth review of these modalities is summarised in this book. In addition, new diagnostic modalities, including risk assessment tools, multi-cancer early detection tests using liquid biopsy, the role of protein biomarkers in breast cancer risk screening, challenges, and hopes for future advances, are also covered in this book.
988			_aSpringer_Medicine_2023
650		7	_2embne _9182522 _aMamas _xCáncer
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-19-7630-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b06/2024 _dz _eb _zSI